HK1212225A1 - 治療性製劑和治療方法 - Google Patents

治療性製劑和治療方法

Info

Publication number
HK1212225A1
HK1212225A1 HK16100185.7A HK16100185A HK1212225A1 HK 1212225 A1 HK1212225 A1 HK 1212225A1 HK 16100185 A HK16100185 A HK 16100185A HK 1212225 A1 HK1212225 A1 HK 1212225A1
Authority
HK
Hong Kong
Prior art keywords
treatment
methods
therapeutic formulation
therapeutic
formulation
Prior art date
Application number
HK16100185.7A
Other languages
English (en)
Inventor
Pamela A Lewis
William H Woller
Original Assignee
Macuclear Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49715792&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1212225(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Macuclear Inc filed Critical Macuclear Inc
Publication of HK1212225A1 publication Critical patent/HK1212225A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK16100185.7A 2012-06-11 2016-01-08 治療性製劑和治療方法 HK1212225A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261658304P 2012-06-11 2012-06-11
PCT/US2013/044617 WO2013188217A1 (en) 2012-06-11 2013-06-06 Therapeutic formulation and methods of treatment

Publications (1)

Publication Number Publication Date
HK1212225A1 true HK1212225A1 (zh) 2016-06-10

Family

ID=49715792

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100185.7A HK1212225A1 (zh) 2012-06-11 2016-01-08 治療性製劑和治療方法

Country Status (9)

Country Link
US (2) US9254287B2 (zh)
JP (1) JP2015519398A (zh)
KR (1) KR20150032552A (zh)
CN (1) CN104768533A (zh)
AU (1) AU2013274582A1 (zh)
HK (1) HK1212225A1 (zh)
SG (1) SG11201408230VA (zh)
TW (1) TW201410245A (zh)
WO (1) WO2013188217A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164419A1 (en) * 2014-04-22 2015-10-29 Acucela Inc. Pupillometric assessment of retinal pharmacodynamics and responses therefrom
AU2015373050B2 (en) 2014-12-30 2022-09-29 Cell Cure Neurosciences Ltd. RPE cell populations and methods of generating same
EP3697285A4 (en) * 2017-10-17 2021-06-30 Apeliotus Technologies, Inc. FUNCTIONAL BIOMARKERS FOR STATIN THERAPY IN AGE-RELATED MACULAR DEGENERATION (AMD)
CA3086815A1 (en) * 2017-12-29 2019-07-04 Cell Cure Neurosciences Ltd. Retinal pigment epithelium cell compositions
CN112007031A (zh) * 2019-05-30 2020-12-01 杏国新药股份有限公司 眼用制剂
US20230201197A1 (en) * 2021-12-29 2023-06-29 Endo Ventures Limited Hydralazine compositions and methods

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4055645A (en) 1976-02-13 1977-10-25 Merck & Co., Inc. Novel anti-hypertensive compositions
US4865599A (en) 1986-08-18 1989-09-12 Houston Biotechnology, Inc. Ophthalmic compositions for treating nerve degeneration
FI873429A (fi) 1986-08-18 1988-02-19 Houston Biotechnology Oftalmologiska kompositioner foer behandling av nervdegenerationer.
US5500230A (en) 1987-01-23 1996-03-19 The General Hospital Corporation Method for treatment of glaucoma with nitrogen containing guanylate cyclase activators
CA1319099C (en) * 1987-01-23 1993-06-15 James A. Nathanson Atriopeptins, guanylate cyclase activators, and phosphodiesterase inhibitors as treatment for glaucoma, hydrocephalus and cerebral edema (cranial fluid volume dysfunction)
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5252607A (en) 1992-01-24 1993-10-12 Texas A&M University System Treatment of low pressure glaucoma and ischemic retinal degeneration
US5459133A (en) 1992-06-05 1995-10-17 Telor Ophthalmic Pharmaceuticals, Inc. Methods and products for treating presbyopia
TW264385B (zh) 1993-05-14 1995-12-01 Taiho Pharmaceutical Co Ltd
US5422116A (en) * 1994-02-18 1995-06-06 Ciba-Geigy Corporation Liquid ophthalmic sustained release delivery system
US5596011A (en) 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
JP3541389B2 (ja) 1996-04-26 2004-07-07 藤沢薬品工業株式会社 ジヒドロピリジン化合物を含有する眼組織末梢循環改善剤
AU4582797A (en) 1996-09-13 1998-04-02 Regents Of The University Of California, The Methods for treatment of retinal diseases
ES2317650T3 (es) 1996-10-28 2009-04-16 Senju Pharmaceutical Co., Ltd. Farmacos para mejorar trastornos circulatorios oculares.
CA2323749A1 (en) 1998-03-06 1999-09-10 William E. Sponsel Composition and method for treating macular disorders
US6028099A (en) 1998-03-13 2000-02-22 John Hopkins University, School Of Medicine Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization
CA2363503C (en) 1999-03-05 2009-03-10 University Of Iowa Research Foundation Diagnostics and therapeutics for drusen associated ocular disorders
IL137429A0 (en) 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
JP2003506394A (ja) 1999-08-10 2003-02-18 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム 視力の保持を容易にするために視神経、脈絡膜、および網膜の血流を増大させるための方法
US6692759B1 (en) 2000-06-28 2004-02-17 The Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
US20030171375A1 (en) 2002-02-13 2003-09-11 Brazzell Romulus Kimbro Method for treating ocular neovascular diseases
JP4599292B2 (ja) 2002-10-30 2010-12-15 エジソン ファーマシューティカルズ， インコーポレイテッド 物理的−化学的特性に基づく治療用化合物の同定
JP2004250347A (ja) 2003-02-18 2004-09-09 Ajinomoto Co Inc 網膜虚血に基づく疾患の治療および／又は予防剤
US20040214215A1 (en) 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
AU2005304770A1 (en) 2004-11-08 2006-05-18 Nicox S.A. Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
AU2006218766A1 (en) * 2005-02-28 2006-09-08 Nicox S.A. Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
US8088773B2 (en) * 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods

Also Published As

Publication number Publication date
CN104768533A (zh) 2015-07-08
AU2013274582A1 (en) 2015-01-22
US20130331393A1 (en) 2013-12-12
JP2015519398A (ja) 2015-07-09
KR20150032552A (ko) 2015-03-26
US9254287B2 (en) 2016-02-09
TW201410245A (zh) 2014-03-16
US9694010B2 (en) 2017-07-04
WO2013188217A1 (en) 2013-12-19
SG11201408230VA (en) 2015-01-29
US20160151368A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
IL261768B (en) Devices and methods for tissue treatment
EP2811897A4 (en) MEDICAL TERMINAL AND APPLICATION METHOD
EP2914326A4 (en) CHEMICAL ABLATION FORMULATIONS AND METHOD FOR THE TREATMENT OF VARIOUS DISEASES
EP2831001A4 (en) COMPOSITION FOR THE TREATMENT OF WATER AND METHOD FOR USE
EP2890815A4 (en) METHOD FOR THE DIAGNOSIS AND TREATMENT OF CANCER
HK1206937A1 (zh) 施用吡非尼酮療法的方法
EP2999474A4 (en) THERAPEUTIC AND METHOD OF USE
EP2819687A4 (en) COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL VASCULAR DISEASE
EP2874647A4 (en) METHOD FOR DIAGNOSIS AND TREATMENT
HK1206623A1 (zh) 藥物組合物和乳腺炎的治療
HK1200348A1 (zh) 用於治療龐貝氏症的方法和材料
GB2500588B (en) Systems and methods of hyperthermal treatment
GB201506561D0 (en) Treatment of amblyopia
HK1212225A1 (zh) 治療性製劑和治療方法
HK1207953A1 (zh) 改進的治療性刺激系統及其使用方法
IL234606A0 (en) Innovative methods and compounds for the treatment of diseases
HK1211213A1 (zh) 涉及粘液素的疾病治療
IL232135A0 (en) Therapeutic combinations and methods for treating melanoma
HK1206646A1 (zh) 常山酮的劑型以及使用方法
PL2892556T3 (pl) Kompozycje i sposoby odnoszące się do leczenia chorób
ZA201408055B (en) Compositions and methods for the treatment of local pain
EP2726079A4 (en) METHOD OF ADMINISTRATION AND TREATMENT
EP2709632A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES
EP2670438A4 (en) SELECTION AND TREATMENT OF PATIENTS
EP2838509A4 (en) FORMULATIONS AND METHOD FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES